Combined wIRA-Hyperthermia and Hypofractionated Re-Irradiation in the Treatment of Locally Recurrent Breast Cancer: Evaluation of Therapeutic Outcome Based on a Novel Size Classification.
LRBC
clinical outcome
locally recurrent breast cancer
novel size classification
re-irradiation
superficial hyperthermia
toxicity
wIRA hyperthermia
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Mar 2020
06 Mar 2020
Historique:
received:
24
01
2020
revised:
02
03
2020
accepted:
03
03
2020
entrez:
12
3
2020
pubmed:
12
3
2020
medline:
12
3
2020
Statut:
epublish
Résumé
Effective tumor control in patients suffering from unresectable locally recurrent breast cancer (LRBC) in pre-irradiated areas can be achieved by re-irradiation combined with superficial hyperthermia. Using this combined modality, total re-irradiation dose and toxicity can be significantly reduced compared to conventionally fractionated treatment schedules with total doses of 60-66 Gy. Applying contact-free, thermography-controlled water-filtered infrared-A superficial hyperthermia, immediately followed by hypofractionated re-irradiation, consisting of 4 Gy once per week up to a total dose of 20 Gy, resulted in high overall response rates even in large-sized tumors. Comparability of clinical data between different combined Hyperthermia (HT)/Radiotherapy (RT) treatment schedules is impeded by the highly individual characteristics of this disease. Tumor size, ranging from microscopic disease and small lesions to large-sized cancer en cuirasse, is described as one of the most important prognostic factors. However, in clinical studies and analyses of LRBC, tumor size has so far been reported in a very heterogeneous way. Therefore, we suggest a novel, simple and feasible size classification (rClasses 0-IV). Applying this classification for the evaluation of 201 patients with pre-irradiated LRBC allowed for a stratification into distinct prognostic groups.
Identifiants
pubmed: 32155740
pii: cancers12030606
doi: 10.3390/cancers12030606
pmc: PMC7139693
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Hyperthermia. 2012;28(6):528-42
pubmed: 22690925
Int J Hyperthermia. 2019;36(1):986-992
pubmed: 31544546
Clin Oncol (R Coll Radiol). 2018 Feb;30(2):73-84
pubmed: 29224899
Radiother Oncol. 2015 Nov;117(2):223-8
pubmed: 26542015
Breast. 2017 Jun;33:159-165
pubmed: 28395234
Radiat Oncol. 2017 Apr 27;12(1):75
pubmed: 28449703
Wien Med Wochenschr. 2002;152(13-14):334-42
pubmed: 12168517
Int J Hyperthermia. 2018;35(1):26-36
pubmed: 29745269
J Natl Compr Canc Netw. 2007 Mar;5(3):345-8
pubmed: 17439763
Clin Breast Cancer. 2017 Nov;17(7):493-502
pubmed: 28396099
Cancers (Basel). 2019 Jun 05;11(6):
pubmed: 31195763
Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):365-75
pubmed: 9457823
Int J Hyperthermia. 2017 Mar;33(2):227-236
pubmed: 27618745
Antioxid Redox Signal. 2007 Aug;9(8):1221-35
pubmed: 17536958
Clin Oncol (R Coll Radiol). 2007 Aug;19(6):418-26
pubmed: 17493790
Strahlenther Onkol. 2019 Apr;195(4):318-326
pubmed: 30607453
Int J Hyperthermia. 2005 Dec;21(8):779-90
pubmed: 16338861
Radiat Oncol. 2015 Sep 17;10:197
pubmed: 26383236
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1073-87
pubmed: 26899950
Adv Drug Deliv Rev. 2020 Jan 23;:
pubmed: 31982475
Radiother Oncol. 2013 Nov;109(2):188-93
pubmed: 23742962
Oncotarget. 2015 Oct 27;6(33):35051-62
pubmed: 26459388
Int J Radiat Oncol Biol Phys. 1980 Nov;6(11):1507-17
pubmed: 7462053
Strahlenther Onkol. 2018 Mar;194(3):206-214
pubmed: 29264624
Cancers (Basel). 2019 Jan 09;11(1):
pubmed: 30634444